NextCure
NXTC
43 hedge funds and large institutions have $24M invested in NextCure in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 5 closing their positions.
13% more capital inflows, than outflows
Capital inflows: $1.06M | Capital outflows: $940K
0.09% more ownership
Funds ownership: 47.75% → 47.84% (+0.09%)
0% more funds holding
Funds holding: 43 → 43 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acuitas Investments
Seattle,
Washington
|
+$471K |
| 2 |
Cardiff Park Advisors
Carlsbad,
California
|
+$430K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$72.1K |
| 4 |
IEQ Capital
Foster City,
California
|
+$61.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$194K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$142K |
| 3 |
Goldman Sachs
New York
|
-$138K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$76.8K |
| 5 |
Marquette Asset Management
Minneapolis,
Minnesota
|
-$76.1K |
NXTC Hedge Fund Activity: Q2 2023 in Review
43 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q2 2023, worth a combined $24M — up 22% from $19.6M a quarter earlier.
Fund positioning in NXTC was balanced in Q2 2023: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 10 trimmed.
The largest buyer was Acuitas Investments, opening a new position worth an estimated $471K. The largest seller was Morgan Stanley, cutting an estimated $194K.
- 43 institutional investors held NextCure (NXTC) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $24M of NextCure stock for Q2 2023, up 22% quarter-over-quarter.
- 5 funds opened new NextCure positions in Q2 2023 and 5 closed out, a net change of 0 holders.
- The largest NextCure buyer in Q2 2023 was Acuitas Investments, an estimated $471K added.
- The largest NextCure seller in Q2 2023 was Morgan Stanley, an estimated $194K sold.
Based on aggregated 13F filings for Q2 2023.